Boyer, James L.

Bile salt transporters: molecular characterization, function, and regulation

Trauner, M., & Boyer, J. L. (2003) · Physiological Reviews

Drug Transport and Resistance MechanismsCholesterol and Lipid Metabolism

Cited by 999

Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases

Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 913

The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis

Roll, J., Boyer, J. L., Barry, D., & Klatskin, G. (1983) · New England Journal of Medicine

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 417

Fibrates and cholestasis

Ghonem, N. S., Assis, D. N., & Boyer, J. L. (2015) · Hepatology

Drug Transport and Resistance MechanismsLiver Diseases and Immunity

Cited by 317

Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids

Marsee, A., Roos, F. J. M., Verstegen, M. M. A., Marsee, A., Roos, F., Verstegen, M., Clevers, H., Vallier, L., Takebe, T., Huch, M., et al. (2021) · Cell Stem Cell

3D Printing in Biomedical ResearchPancreatic function and diabetes

Cited by 310

Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats

Perry, R. J., Zhang, D., Zhang, X.-M., Boyer, J. L., & Shulman, G. I. (2015) · Science

Liver Disease Diagnosis and TreatmentMetabolism, Diabetes, and Cancer

Cited by 283

Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay

Mayo, M. J., Parkes, J., Adams-Huet, B., Combes, B., Mills, A. S., Markin, R. S., Rubin, R., Wheeler, D., Contos, M., West, A. B., et al. (2008) · Hepatology

Liver Diseases and ImmunityLiver Disease Diagnosis and Treatment

Cited by 198

Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years

Mahl, T. C., Shockcor, W., & Boyer, J. L. (1994) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 163

Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases

Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2022) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 146

Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells

He, H., Mennone, A., Boyer, J. L., & Cai, S.-Y. (2011) · Hepatology

Liver physiology and pathologyLiver Diseases and Immunity

Cited by 119

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases

Lynch, K. D., Chapman, R. W., Keshav, S., Montano-Loza, A. J., Mason, A. L., Kremer, A. E., Vetter, M., de Krijger, M., Ponsioen, C. Y., Trivedi, P., et al. (2020) · Clinical Gastroenterology and Hepatology

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 105

A Positive Feedback Loop of TET3 and TGF-β1 Promotes Liver Fibrosis

Xu, Y., Sun, X., Zhang, R., Cao, T., Cai, S.-Y., Boyer, J. L., Zhang, X., Li, D., & Huang, Y. (2020) · Cell Reports

Liver physiology and pathologyTGF-β signaling in diseases

Cited by 73

Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol

Ghonem, N. S., Auclair, A. M., Hemme, C. L., Gallucci, G. M., de la Rosa Rodriguez, R., Boyer, J. L., & Assis, D. N. (2020) · Clinical Pharmacology & Therapeutics

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 57

Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis

Gallucci, G. M., Alsuwayt, B., Auclair, A. M., Boyer, J. L., Assis, D. N., & Ghonem, N. S. (2022) · Inflammation

Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors

Cited by 46

PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases

Gallucci, G. M., Hayes, C. M., Boyer, J. L., Barbier, O., Assis, D. N., & Ghonem, N. S. (2024) · Cells

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 40

All-Trans-Retinoic Acid Improves Cholestasis in α-Naphthylisothiocyanate–Treated Rats and Mdr2−/− Mice

Cai, S.-Y., Mennone, A., Soroka, C. J., & Boyer, J. L. (2014) · The Journal of Pharmacology and Experimental Therapeutics

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 36

Adjunct Fenofibrate Up‐regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis

Gallucci, G. M., Trottier, J., Hemme, C., Assis, D. N., Boyer, J. L., Barbier, O., & Ghonem, N. S. (2021) · Hepatology Communications

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 26